Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Current Leases (2022 - 2025)

Historic Current Leases for Ovid Therapeutics (OVID) over the last 4 years, with Q3 2025 value amounting to $1.4 million.

  • Ovid Therapeutics' Current Leases rose 731.15% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 731.15%. This contributed to the annual value of $1.3 million for FY2024, which is 722.31% up from last year.
  • According to the latest figures from Q3 2025, Ovid Therapeutics' Current Leases is $1.4 million, which was up 731.15% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, Ovid Therapeutics' Current Leases peaked at $1.4 million during Q3 2025, and registered a low of $533946.0 during Q4 2022.
  • For the 4-year period, Ovid Therapeutics' Current Leases averaged around $1.2 million, with its median value being $1.3 million (2024).
  • As far as peak fluctuations go, Ovid Therapeutics' Current Leases surged by 13335.69% in 2023, and later surged by 720.37% in 2025.
  • Over the past 4 years, Ovid Therapeutics' Current Leases (Quarter) stood at $533946.0 in 2022, then surged by 133.36% to $1.2 million in 2023, then rose by 7.22% to $1.3 million in 2024, then rose by 5.46% to $1.4 million in 2025.
  • Its Current Leases stands at $1.4 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.4 million for Q1 2025.